A fully humanized transgenic mouse model of Huntington disease
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
A fully humanized transgenic mouse model of Huntington disease. / Southwell, Amber L; Warby, Simon C; Carroll, Jeffrey B; Doty, Crystal N; Skotte, Niels H; Zhang, Weining; Villanueva, Erika B; Kovalik, Vlad; Xie, Yuanyun; Pouladi, Mahmoud A; Collins, Jennifer A; Yang, X William; Franciosi, Sonia; Hayden, Michael R.
I: Human Molecular Genetics, Bind 22, Nr. 1, 01.01.2013, s. 18-34.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A fully humanized transgenic mouse model of Huntington disease
AU - Southwell, Amber L
AU - Warby, Simon C
AU - Carroll, Jeffrey B
AU - Doty, Crystal N
AU - Skotte, Niels H
AU - Zhang, Weining
AU - Villanueva, Erika B
AU - Kovalik, Vlad
AU - Xie, Yuanyun
AU - Pouladi, Mahmoud A
AU - Collins, Jennifer A
AU - Yang, X William
AU - Franciosi, Sonia
AU - Hayden, Michael R
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Silencing the mutant huntingtin gene (muHTT) is a direct and simple therapeutic strategy for the treatment of Huntington disease (HD) in principle. However, targeting the HD mutation presents challenges because it is an expansion of a common genetic element (a CAG tract) that is found throughout the genome. Moreover, the HTT protein is important for neuronal health throughout life, and silencing strategies that also reduce the wild-type HTT allele may not be well tolerated during the long-term treatment of HD. Several HTT silencing strategies are in development that target genetic sites in HTT that are outside of the CAG expansion, including HD mutation-linked single-nucleotide polymorphisms and the HTT promoter. Preclinical testing of these genetic therapies has required the development of a new mouse model of HD that carries these human-specific genetic targets. To generate a fully humanized mouse model of HD, we have cross-bred BACHD and YAC18 on the Hdh(-/-) background. The resulting line, Hu97/18, is the first murine model of HD that fully genetically recapitulates human HD having two human HTT genes, no mouse Hdh genes and heterozygosity of the HD mutation. We find that Hu97/18 mice display many of the behavioral changes associated with HD including motor, psychiatric and cognitive deficits, as well as canonical neuropathological abnormalities. This mouse line will be useful for gaining additional insights into the disease mechanisms of HD as well as for testing genetic therapies targeting human HTT.
AB - Silencing the mutant huntingtin gene (muHTT) is a direct and simple therapeutic strategy for the treatment of Huntington disease (HD) in principle. However, targeting the HD mutation presents challenges because it is an expansion of a common genetic element (a CAG tract) that is found throughout the genome. Moreover, the HTT protein is important for neuronal health throughout life, and silencing strategies that also reduce the wild-type HTT allele may not be well tolerated during the long-term treatment of HD. Several HTT silencing strategies are in development that target genetic sites in HTT that are outside of the CAG expansion, including HD mutation-linked single-nucleotide polymorphisms and the HTT promoter. Preclinical testing of these genetic therapies has required the development of a new mouse model of HD that carries these human-specific genetic targets. To generate a fully humanized mouse model of HD, we have cross-bred BACHD and YAC18 on the Hdh(-/-) background. The resulting line, Hu97/18, is the first murine model of HD that fully genetically recapitulates human HD having two human HTT genes, no mouse Hdh genes and heterozygosity of the HD mutation. We find that Hu97/18 mice display many of the behavioral changes associated with HD including motor, psychiatric and cognitive deficits, as well as canonical neuropathological abnormalities. This mouse line will be useful for gaining additional insights into the disease mechanisms of HD as well as for testing genetic therapies targeting human HTT.
KW - Animals
KW - Disease Models, Animal
KW - Gene Silencing
KW - Humans
KW - Huntington Disease
KW - Mice
KW - Mice, Transgenic
KW - Mutation
KW - Polymorphism, Single Nucleotide
KW - Promoter Regions, Genetic
KW - Rotarod Performance Test
U2 - 10.1093/hmg/dds397
DO - 10.1093/hmg/dds397
M3 - Journal article
C2 - 23001568
VL - 22
SP - 18
EP - 34
JO - Human Molecular Genetics
JF - Human Molecular Genetics
SN - 0964-6906
IS - 1
ER -
ID: 153451538